• 1
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 4348.
  • 2
    Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 7480.
  • 3
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander TB. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 11039.
  • 4
    Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, De Moura MC. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41: 1729.
  • 5
    Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986; 21: 10913.
  • 6
    Lonardo A, Bellini M, Tondelli E, et al. Nonalcoholic steatohepatitis and the ‘bright liver syndrome’: should a recently expanded clinical entity be further expanded? Am J Gastroenterol 1995; 90: 20724.
  • 7
    Neuschwander-Tetri BA & Bacon BR. Nonalcoholic steatohepatitis. Med Clin North Am 1996; 80: 114766.
  • 8
    Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 13745.
  • 9
    Palmer M & Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 140813.
  • 10
    Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 2249.
  • 11
    Czaja MJ, Weiner FR, Flanders KC, et al. In vitro and in vivo association of transforming growth factor-β1 with hepatic fibrosis. J Cell Biol 1989; 108: 247782.
  • 12
    Eghbali-Fatourechi G, Sieck GC, Prakash YS, et al. Type I procollagen production and cell proliferation is mediated by transforming growth factor-β in a model of hepatic fibrosis. Endocrinology 1996; 137: 1894903.
  • 13
    Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995; 92: 25726.
  • 14
    Poli G, Albano E, Biasi F, et al. Lipid peroxidation stimulated by carbon tetrachloride or iron and hepatocyte death: protective effect of vitamin E. In: Poli G, Cheeseman KH, Diazani MU, Slater TF, eds. Free Radicals in Liver Injury. Oxford: IRL Press Ltd, 1985: 207–15.
  • 15
    Parola M, Muraca R, Dianzani I, et al. Vitamin E dietary supplementation inhibits transforming growth factor β1 gene expression in the rat liver. FEBS Lett 1992; 308: 26770.
  • 16
    Parola M, Leonarduzzi G, Biasi F, et al. Vitamin E dietary supplementation protects against carbon tetrachloride- induced chronic liver damage and cirrhosis. Hepatology 1992; 16: 101421.
  • 17
    Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatrics 2000; 136: 7348.
  • 18
    Knodell R, Ishak K, Black W. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 4315.
  • 19
    Danielpour D, Kim KY, Dart LL, Watanabe S, Roberts AB, Sporn MB. Sandwich enzyme-linked immunosorbent assays (SELISAs) quantitate and distinguish two forms of transforming growth factor-β (TGF-β1 and TGF-β2) in complex biological fluids. Growth Factors 1989; 2: 6171.
  • 20
    Oberhammer FA, Pavelka M, Sharma S, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc Natl Acad Sci USA 1992; 89: 540812.
  • 21
    Jakowlew SB, Mead JE, Danielpour D, Wu J, Roberts AB, Fausto N. Transforming growth factor-β (TGF-β) isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-β. Cell Regul 1991; 27: 53548.
  • 22
    De Bleser P, Niki T, Rogiers V, Geerts A. Transforming growth factor-β gene expression in normal and fibrotic rat liver. J Hepatol 1997; 26: 88693.
  • 23
    Nelson DR, Gonzalez PR, Qian K, et al. Transforming growth factor-β1 in chronic hepatitis C. J Viral Hepat 1997; 4: 2935.
  • 24
    Nagy P, Schaff Z, Lapis K. Immunohistochemical detection of transforming growth factor-β1 in fibrotic liver diseases. Hepatology 1991; 14: 26973.
  • 25
    Annoni G, Weiner FR, Zern MA. Increased transforming growth factor-β1 gene expression in human liver disease. J Hepatol 1992; 14: 25964.
  • 26
    Matsuoka M & Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor β: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology 1990; 11: 599605.
  • 27
    Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990; 6: 597643.
  • 28
    Knapp S, Thalhammer F, Locker GJ, et al. Prognostic value of MIP-1α, TGF-β2, sELAM-1, and sVCAM-1 in patients with gram-positive sepsis. Clin Immunol Immunopathol 1998; 87: 13944.DOI: 10.1006/clin.1998.4523
  • 29
    Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 8346.
  • 30
    Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 4905.
  • 31
    Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 14647.